Yale University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Yale University sits in the top decile of US sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count).
Yale University: 1,492 sponsored US clinical trials, 254 recruiting.
Yale University sponsors 1,492 registered US clinical trials on ClinicalTrials.gov, 254 of them currently recruiting, and 1,005 completed. 99 of these trials are in Phase 3-4 (later-stage) and 579 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use Disorder, with 19 trials.
Top-decile sponsor footprint
Yale University ranks in the top decile of sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,005 of 1,138 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,492 total, page 24 of 30
Reproductive Medicine Network Biologic Specimen Repository
NCT01180387
Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors
NCT01177007
Detecting Heart Disease Using First Pass Imaging With Gated SPECT Perfusion
NCT01137409
Effect of Formoterol on the Counterregulatory Hormonal Response to Hypoglycemia in Type 1 Diabetes.
NCT01194479
Alcohol Pharmacotherapy for HIV+ Prisoners
NCT01077310
Benefits Management for People With Psychiatric Disabilities
NCT01329393
Study of Computer-Based Treatment for Drug Dependence
NCT01315184
Trial of Mentalization-Based Therapy for Substance Using Mothers of Infants and Toddlers
NCT01240993
Evaluating a New Echocardiography Imaging Procedure for Evaluating Heart Function
NCT00661323
Neural Functioning of Feeding Centers in Obese Youth
NCT01808846
Incentive-based Intervention for Smoking Cessation and Prevention in High Schools
NCT01173835
N-acetylcysteine (NAC) for Children With Tourette Syndrome
NCT01172288
Internet-Administered Smoking Cessation Treatment for Overweight and Obese Smokers
NCT01259466
Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation
NCT01044862
Tdap Vaccination for Infant Caregivers
NCT01233401
Deceased Donor Biomarkers and Recipient Outcomes
NCT01848249
Microsurgical Varicocelectomy Versus No Surgery in Men With a Palpable Varicocele and an Abnormal Semen Analysis
NCT00767338
Modafinil, Sleep Architecture and Cocaine Relapse
NCT01137396
Continuous Glucose Monitoring in Critically Ill Surgical Patients
NCT01108640
Ketamine for Low Mood States in the ER
NCT01209845
Galantamine Effects on Nicotine Responses in Smokers
NCT01417429
The Effects of Physiologic Oxygen Tension on Clinical In Vitro Fertilization Outcomes
NCT01010386
HIV Testing and Brief Alcohol Intervention for Young Drinkers in the Emergency Department
NCT01573065
The Effects of Cannabidiol and ∆-9-THC in Humans
NCT01180374
A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in Schizophrenia
NCT01232790
Regulation of Arginine-vasopressin (AVP)
NCT02626832
Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease
NCT01472874
Effects of Vitamin D Dose and Genotype of the Binding Protein in Infants and Children
NCT01050387
Abstinence-Linked Money Management Multisite
NCT01327586
Dosing Study of Cranberry Capsules for the Prevention of Bacteriuria in Nursing Home Residents
NCT01033383
Enhancing a High School Based Smoking Cessation Program
NCT01145001
Milestones of Adjustment Post-Psychosis
NCT01192594
N-Acetylcysteine for Pediatric Trichotillomania
NCT00993265
Effect of Varenicline on Fixed-Dose Alcohol Administration in Participants With Alcohol Use Disorders
NCT01000987
A Trial to Reduce Pneumonia in Nursing Home Residents
NCT00975780
Lifestyle Modification for Weight Loss in Schizophrenia
NCT00990925
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
NCT01561833
Nicotine Vaccination and Nicotinic Receptor Occupancy
NCT00996034
Minding the Baby Home Visiting: Program Evaluation
NCT01458145
An Intervention to Improve Outcomes in Patients With Advanced Cancer
NCT01272024
Reducing Obesity and Type 2 Diabetes in High Risk Youth
NCT01560676
Prevention of Type 2 Diabetes in Children With a Family-based Healthy Lifestyle Program
NCT01030978
Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse
NCT00585780
Clinical Trial of Integrated Treatment for Pain and Opioid Dependence
NCT00634803
Galantamine Effects on Cognitive Function in Marijuana Users
NCT00969696
Positron Emission Tomography (PET) Imaging of Pancreatic Beta-Cell Mass in Healthy and Type 1 Diabetic Patients
NCT00958997
Cognitive Behavioral Therapy for Insomnia in Stable Heart Failure
NCT02827799
The Development of a Domestic Violence Perpetrator Collusion Measurement Tool
NCT01942616
Smoking Cessation Treatment for Head and Neck Cancer Patients
NCT00931021
A Study to Examine the Human Gastrointestinal Tract Using the Confocal Endomicroscope
NCT01262937
What is open in the Yale University pipeline
254 recruiting of 1,492 indexed (17% open); 1,005 completed (67%).
Phase mix: 99 late (III/IV) vs 579 early (I/II) (early-phase heavy).
Top condition: Opioid Use Disorder (19 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Yale University: open-pipeline peers nationwide
Peers matched on 1,492 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,492 trials (± recruiting share)
- Washington University School of Medicine · 1,502 trials · 14% recruiting
- Johns Hopkins University · 1,448 trials · 17% recruiting
- University of Pennsylvania · 1,423 trials · 14% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
Sponsors near 17% open enrollment (± trial volume)
- NYU Langone Health · 17% recruiting · 1,164 trials
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
Related
What to do with this Yale University page
1,492 registered trials is a research-attention snapshot, not an endorsement of Yale University or any single study.
- 254 of Yale University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Opioid Use Disorder is the condition Yale University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Yale University pipeline card: 1,492 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.